Goldman Sachs assigned Nuvalent (NUVL) a Buy rating with a $105 price target having previously initiated coverage at Not Rated. Upon the completion of zidesamtinib’s pivotal Phase 2 ARROS-1 topline results in TKI pre-treated ROS1-positive non-small cell lung cancer patients, the firm moved on from its previous “Early-Stage Biotech” designation, telling investors that its Buy rating is supported by zidesamtinib’s best-in-class efficacy and safety profile demonstrated in both of its Phase 1/2 studies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent price target raised to $112 from $105 at Baird
- Nuvalent’s Zidesamtinib: A Promising Blockbuster in the ROS1 Inhibitor Landscape
- Nuvalent price target raised to $140 from $125 at Leerink
- Nuvalent price target raised to $130 from $110 at H.C. Wainwright
- Nuvalent’s Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile